{"id":3334,"date":"2025-03-24T14:15:34","date_gmt":"2025-03-24T11:15:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3334"},"modified":"2025-03-24T14:26:43","modified_gmt":"2025-03-24T11:26:43","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk\/","title":{"rendered":"Entrada Therapeutics recebe autoriza\u00e7\u00e3o no Reino Unido para iniciar ELEVATE-45-201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Entrada Therapeutics anunciou que recebeu autoriza\u00e7\u00e3o da Ag\u00eancia Reguladora de Medicamentos e Produtos de Sa\u00fade (MHRA) e do Comit\u00ea de \u00c9tica em Pesquisa do Reino Unido para iniciar o ELEVATE-45-201. O ELEVATE-45-201 \u00e9 um estudo cl\u00ednico de dose m\u00faltipla ascendente (MAD) de Fase 1\/2 para avaliar o medicamento experimental ENTR-601-45 da Entrada para o tratamento potencial da distrofia muscular de Duchenne (DMD) em pacientes com uma muta\u00e7\u00e3o confirmada no gene DMD pass\u00edvel de salto do exon 45.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Saber mais: <a href=\"https:\/\/dmdwarrior.com\/pt\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" data-type=\"post\" data-id=\"1445\" rel=\"noreferrer noopener\">O que \u00e9 Exon Skipping?<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics, announced it has received authorization from the United Kingdom\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1\/2 multiple ascending dose (MAD) clinical study to evaluate Entrada\u2019s investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3335,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[320,321,234,317,318,319,48,322],"class_list":["post-3334","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-45-201","tag-entr-601-45","tag-entrada-therapeutics","tag-exon-45","tag-exon-45-skipping","tag-exon-45-skipping-therapy","tag-uk","tag-united-kingdom"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=3334"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/3334\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/3335"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=3334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=3334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=3334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}